| Katie Rennie, | |
|
201 W Walnut St, Columbus, KS 66725-1121 | |
| (620) 429-1860 | |
| Not Available |
| Full Name | Katie Rennie |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 201 W Walnut St, Columbus, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710427083 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 2757 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Katie Rennie, Po Box 550, Riverton, KS 66770-0550 Ph: () - | Katie Rennie, 201 W Walnut St, Columbus, KS 66725-1121 Ph: (620) 429-1860 |
News Archive
Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.
Researchers at the University of Georgia have discovered that a chemical compound commonly found in coffee may help prevent some of the damaging effects of obesity.
A team of researchers from the Spanish National Cancer Research Centre (CNIO), headed by CNIO Director Mar-a Blasco, has demonstrated in a pioneering study on mammals that longevity is defined at a molecular level by the length of telomeres. The work-which is published today in the online edition of the journal Cell Reports-opens the door to further study of these cellular components in order to calculate the rate at which cells age and thus be able to determine life expectancy for a particular organism.
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
Insights from a genetic condition that causes brain cancer are helping scientists better understand the most common type of brain tumor in children.
› Verified 6 days ago
Heather Caldwell, T-LMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 201 W Walnut St, Columbus, KS 66725 Phone: 620-429-1860 Fax: 620-429-1041 |